Abstract Number: 2238 • ACR Convergence 2024
The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status
Background/Purpose: Disease activity associated with cardiovascular (CV) risk in rheumatoid arthritis (RA). Females with RA exhibit higher disease activity than males. Yet, males with RA…Abstract Number: 2257 • ACR Convergence 2024
Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis
Background/Purpose: Immunobiological drugs emerged as a revolutionary option for treating inflammatory chronic rheumatic diseases, particularly rheumatoid arthritis (RA). However, the extremely high costs associated with…Abstract Number: 2276 • ACR Convergence 2024
Use of Methotrexate and TNF-α Inhibitors in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease: A Survey of Rheumatologists
Background/Purpose: Interstitial lung disease (ILD) is among the most common extra-articular manifestations of RA, with symptomatic disease prevalent in approximately 10% of patients.1 Patients with…Abstract Number: 2539 • ACR Convergence 2024
Telocytes Integrated into Mast Cells and Joint-Draining Lymphatic Vessels Potentially Regulate Lymphatic Clearance
Background/Purpose: Rheumatoid arthritis (RA) patients and TNF-transgenic mice have lymphatic dysfunction (1). Recently, we showed mast cells involvement, as genetic ablation and drug inhibition decreased…Abstract Number: 2636 • ACR Convergence 2024
Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Background/Purpose: In a previous study, we reported the discovery and evaluation of a serum protein (22 peptide) signature (RAPsA Dx) which, when using random forest machine…Abstract Number: 0040 • ACR Convergence 2024
Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis
Background/Purpose: New precision medicine guided therapies targeting alternate disease driving processes are required to improve clinical outcomes in RA. The complement pathway has long been…Abstract Number: 0057 • ACR Convergence 2024
Flow Cytometry of Cells Within Induced Sputum from Individuals At-Risk for RA Reveals Relative Expansion of Small Macrophages
Background/Purpose: Serum elevations of ACPA in the absence of inflammatory arthritis is a well-established risk factor for the future development of clinical RA. The lung…Abstract Number: 0140 • ACR Convergence 2024
Estimation of 10-year Cardiovascular (CV) Risk and Traditional CV Risk Factors Distribution in Patients with Rheumatoid Arthritis from Three Italian Macro-areas
Background/Purpose: Geographic origins can significantly impact people’s health, particularly in Italy, where regional health disparities are among the most pronounced [1]. Rheumatoid arthritis (RA) is…Abstract Number: 0222 • ACR Convergence 2024
The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound
Background/Purpose: There are discrepancies between physical examination and Ultrasound (US) in detecting inflammation in Rheumatoid Arthritis (RA). In this study, we aimed to understand, according…Abstract Number: 0364 • ACR Convergence 2024
Exploring 24-Hour Temporal Trends in Symptoms and Treatment of Rheumatic Disease Through Google Search Trends
Background/Purpose: Symptoms of rheumatic diseases such as joint stiffness and pain are known to peak in the early morning hours. In the digital age, tracking…Abstract Number: 0461 • ACR Convergence 2024
Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis
Background/Purpose: The complement (C) system has been implicated in the etiopathogenesis of rheumatoid arthritis (RA). We aimed to examine the correlation between an in-depth evaluation…Abstract Number: 0477 • ACR Convergence 2024
The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of rheumatoid arthritis (RA) that severely impacts the health outcomes of RA patients. Despite this, the…Abstract Number: 0495 • ACR Convergence 2024
Correlation Between Triglyceride/Glucose Index and Functional Capacity in Rheumatoid Arthritis Patients
Background/Purpose: The triglyceride/glucose index (TGI) is a metabolic marker associated with insulin resistance and cardiovascular risk. In patients with Rheumatoid Arthritis (RA), chronic inflammation and…Abstract Number: 0511 • ACR Convergence 2024
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Background/Purpose: In pts with RA, high RF levels are associated with poor prognosis, higher disease activity, and decreased response to monoclonal antibodies targeting tumor necrosis…Abstract Number: 0529 • ACR Convergence 2024
Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data
Background/Purpose: Individuals with rheumatoid arthritis (RA) may discontinue b/tsDMARDs due to treatment failure, adverse events or costs. Little is known about b/tsDMARDs discontinuation among Medicare…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 188
- Next Page »